Scynexis (SCYX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026)
Scynexis (SCYX) Net Income towards Common Stockholders Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Scynexis | 61.37 Mn | -53.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.39% |
| Mar 31, 2026 | -28.57% |
| Dec 31, 2025 | 18.79% |
| Sep 30, 2025 | -62.84% |
| Jun 30, 2025 | -1.53% |
| Mar 31, 2025 | 5.09% |
| Dec 31, 2024 | 19.84% |
| Sep 30, 2024 | 18.77% |
| Jun 30, 2024 | -11.46% |
| Mar 31, 2024 | 15.25% |
| Dec 31, 2023 | -18.87% |
| Sep 30, 2023 | 30.66% |
| Jun 30, 2023 | 83.65% |
| Mar 31, 2023 | -41.14% |
| Dec 31, 2022 | -21.35% |
| Sep 30, 2022 | -42.18% |
| Jun 30, 2022 | -10.88% |
| Mar 31, 2022 | 2.83% |
| Dec 31, 2020 | -31.97% |
| Sep 30, 2020 | 16.09% |